Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

Prior treatment

• Blood transfusion performed during operation or within 2 weeks before operation;
• Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;

Other illness

• Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;
• Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;
• Significant impairment of important organ function;
• Other conditions in which the investigator believes that the patient should not participate in this trial.

Other

• Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;

• Age ≥ 18 years old, regardless of gender;
• Histologically confirmed, recurrent or metastatic colorectal cancer;
• Eligible to receive radiotherapy in combination with standard-of-care chemotherapy, with or without PD-1 inhibitors.
• With expected survival of more than 6 months;
• The subjects (or their legal representative / Guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.